47.99
price down icon0.93%   -0.45
after-market Dopo l'orario di chiusura: 47.99
loading
Precedente Chiudi:
$48.44
Aprire:
$48.54
Volume 24 ore:
891.56K
Relative Volume:
0.51
Capitalizzazione di mercato:
$4.73B
Reddito:
$4.10M
Utile/perdita netta:
$-568.53M
Rapporto P/E:
-7.7256
EPS:
-6.2118
Flusso di cassa netto:
$-401.18M
1 W Prestazione:
+3.12%
1M Prestazione:
-12.01%
6M Prestazione:
-3.94%
1 anno Prestazione:
-14.70%
Intervallo 1D:
Value
$47.31
$49.03
Intervallo di 1 settimana:
Value
$45.89
$49.03
Portata 52W:
Value
$44.12
$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Nome
Crispr Therapeutics Ag
Name
Telefono
(617) 315-4600
Name
Indirizzo
BAARERSTRASSE 14, ZUG
Name
Dipendente
393
Name
Cinguettio
@crisprtx
Name
Prossima data di guadagno
2026-08-03
Name
Ultimi documenti SEC
Name
CRSP's Discussions on Twitter

Compare CRSP vs VRTX, REGN, ARGX, RVMD, ONC

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CRSP icon
CRSP
Crispr Therapeutics Ag
47.99 4.60B 4.10M -568.53M -401.18M -6.2118
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.10 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
762.63 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
853.82 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
187.53 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
316.01 33.81B 5.76B 514.49M 1.10B 4.4813

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-09-18 Iniziato JP Morgan Overweight
2025-02-14 Aggiornamento Evercore ISI In-line → Outperform
2025-02-12 Aggiornamento TD Cowen Sell → Hold
2025-02-03 Iniziato H.C. Wainwright Buy
2024-08-06 Reiterato Needham Buy
2024-08-02 Iniziato Rodman & Renshaw Buy
2024-06-28 Ripresa Guggenheim Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-11 Downgrade TD Cowen Market Perform → Underperform
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-27 Iniziato Mizuho Buy
2023-08-17 Aggiornamento Citigroup Neutral → Buy
2023-05-30 Iniziato William Blair Outperform
2023-04-13 Iniziato Cantor Fitzgerald Overweight
2023-03-21 Iniziato Bernstein Mkt Perform
2023-03-17 Iniziato Bryan Garnier Buy
2023-03-07 Iniziato Robert W. Baird Neutral
2022-10-11 Iniziato Morgan Stanley Underweight
2022-08-09 Downgrade Barclays Overweight → Equal Weight
2022-06-23 Downgrade Evercore ISI Outperform → In-line
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-04-28 Iniziato Credit Suisse Neutral
2021-12-07 Iniziato Cowen Market Perform
2021-10-19 Iniziato SVB Leerink Outperform
2021-06-14 Aggiornamento Citigroup Sell → Neutral
2021-04-21 Aggiornamento Jefferies Hold → Buy
2021-03-04 Iniziato JMP Securities Mkt Outperform
2020-12-10 Reiterato Chardan Capital Markets Buy
2020-12-10 Downgrade Jefferies Buy → Hold
2020-12-10 Reiterato Needham Buy
2020-12-07 Downgrade Wells Fargo Overweight → Equal Weight
2020-10-23 Iniziato RBC Capital Mkts Sector Perform
2020-10-05 Iniziato BofA Securities Buy
2020-07-28 Reiterato Needham Buy
2020-07-14 Iniziato SunTrust Buy
2020-06-15 Reiterato Canaccord Genuity Buy
2020-03-05 Iniziato Stifel Hold
2020-02-03 Downgrade Evercore ISI Outperform → In-line
2019-11-19 Aggiornamento William Blair Mkt Perform → Outperform
2019-11-12 Aggiornamento Oppenheimer Perform → Outperform
2019-08-01 Iniziato Jefferies Buy
2019-07-26 Iniziato Canaccord Genuity Buy
2019-06-10 Iniziato ROTH Capital Buy
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-14 Iniziato William Blair Mkt Perform
2019-01-28 Downgrade Goldman Buy → Neutral
2019-01-22 Downgrade Citigroup Neutral → Sell
Mostra tutto

Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie

pulisher
Jul 28, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance UK

Jul 28, 2026
pulisher
Jul 28, 2026

CRSP|CRISPR Therapeutics AG|Price:46.770|Chg%:+0.230 - TradingKey

Jul 28, 2026
pulisher
Jul 27, 2026

BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

CRISPR Therapeutics AG (CRSP) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Jul 27, 2026
pulisher
Jul 27, 2026

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close. - The Motley Fool

Jul 27, 2026
pulisher
Jul 26, 2026

CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Jul 26, 2026
pulisher
Jul 26, 2026

TradingKey - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 25, 2026
pulisher
Jul 25, 2026

Affinity Asset Advisors LLC Buys Shares of 150,000 CRISPR Therapeutics AG $CRSP - MarketBeat

Jul 25, 2026
pulisher
Jul 25, 2026

CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T - Sahm

Jul 25, 2026
pulisher
Jul 24, 2026

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Jul 24, 2026
pulisher
Jul 24, 2026

KBC Group NV Acquires 113,997 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Jul 24, 2026
pulisher
Jul 24, 2026

CRISPR Therapeutics (CRSP) Short Interest & Short Float | Updated Jul 2026 - MarketBeat

Jul 24, 2026
pulisher
Jul 23, 2026

CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary - Quartr

Jul 23, 2026
pulisher
Jul 23, 2026

CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary - Quartr

Jul 23, 2026
pulisher
Jul 23, 2026

Monashee Investment Management LLC Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat

Jul 23, 2026
pulisher
Jul 22, 2026

Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs - The Globe and Mail

Jul 22, 2026
pulisher
Jul 22, 2026

CRSP: CRISPR Therapeutics AG Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Jul 22, 2026
pulisher
Jul 22, 2026

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool

Jul 22, 2026
pulisher
Jul 22, 2026

Citizens reiterates CRISPR Therapeutics stock rating on pipeline progress - Investing.com

Jul 22, 2026
pulisher
Jul 22, 2026

Citizens reiterates CRISPR Therapeutics stock rating on pipeline progress By Investing.com - Investing.com UK

Jul 22, 2026
pulisher
Jul 21, 2026

US226712AA5 Bond Profile — Key Metrics - TradingView

Jul 21, 2026
pulisher
Jul 21, 2026

CRISPR Therapeutics AG (CRSP) declines more than market: Some information for investors - MSN

Jul 21, 2026
pulisher
Jul 21, 2026

CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc. - MarketBeat

Jul 21, 2026
pulisher
Jul 21, 2026

CRISPR Therapeutics: A Catalyst-Rich 12 Months Ahead (NASDAQ:CRSP) - Seeking Alpha

Jul 21, 2026
pulisher
Jul 20, 2026

CRISPR Therapeutics stock trades steady as gene-editing pipeline advances after quarterly loss narro - AD HOC NEWS

Jul 20, 2026
pulisher
Jul 19, 2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - ADVFN

Jul 19, 2026
pulisher
Jul 18, 2026

Nwam LLC Sells 52,670 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Jul 18, 2026
pulisher
Jul 18, 2026

Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued? - Yahoo Finance UK

Jul 18, 2026
pulisher
Jul 17, 2026

Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path? - Yahoo Finance

Jul 17, 2026
pulisher
Jul 17, 2026

(CRSP) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Jul 17, 2026
pulisher
Jul 17, 2026

CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns - simplywall.st

Jul 17, 2026
pulisher
Jul 17, 2026

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 17, 2026
pulisher
Jul 17, 2026

CRISPR Therapeutics (CRSP) Slides For Six Days, Is The Stock Now Cheap? - Yahoo Finance

Jul 17, 2026
pulisher
Jul 17, 2026

Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash? - Sahm

Jul 17, 2026
pulisher
Jul 16, 2026

Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market - Yahoo Finance

Jul 16, 2026
pulisher
Jul 15, 2026

Citigroup Maintains CRISPR Therapeutics (CRSP) Buy Recommendation - MSN

Jul 15, 2026
pulisher
Jul 14, 2026

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 14, 2026
pulisher
Jul 14, 2026

Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP - MarketBeat

Jul 14, 2026
pulisher
Jul 11, 2026

Crispr Therapeutics AG Slides Despite Bullish Wall Street - TipRanks

Jul 11, 2026
pulisher
Jul 11, 2026

CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Jul 11, 2026
pulisher
Jul 10, 2026

CRSP Technical Analysis | Trend, Signals & Chart Patterns - ChartMill

Jul 10, 2026
pulisher
Jul 10, 2026

CRISPR Therapeutics AG (CRSP) stock dips while market gains: Key facts - MSN

Jul 10, 2026
pulisher
Jul 10, 2026

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts - Yahoo Finance

Jul 10, 2026
pulisher
Jul 10, 2026

3 Reasons to Buy CRISPR Therapeutics Stock - The Motley Fool

Jul 10, 2026
pulisher
Jul 10, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com

Jul 10, 2026
pulisher
Jul 10, 2026

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - AOL.com

Jul 10, 2026
pulisher
Jul 08, 2026

CRSP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $80 - GuruFocus

Jul 08, 2026

Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Crispr Therapeutics Ag Azioni (CRSP) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
KASINGER JAMES R.
General Counsel and Secretary
Mar 23 '26
Sale
46.78
3,182
148,854
94,308
Kulkarni Samarth
Chief Executive Officer
Mar 23 '26
Sale
46.78
10,020
468,736
255,501
Prasad Raju
Chief Financial Officer
Mar 23 '26
Sale
46.78
3,708
173,460
15,565
Patel Naimish
Chief Medical Officer
Mar 16 '26
Sale
48.26
3,150
152,019
13,143
Prasad Raju
Chief Financial Officer
Mar 16 '26
Sale
48.26
9,869
476,278
13,773
KASINGER JAMES R.
General Counsel and Secretary
Mar 16 '26
Sale
48.26
3,450
166,497
91,240
Kulkarni Samarth
Chief Executive Officer
Mar 16 '26
Sale
48.26
10,349
499,443
245,834
KASINGER JAMES R.
General Counsel and Secretary
Mar 11 '26
Sale
52.80
2,800
147,840
87,815
Kulkarni Samarth
Chief Executive Officer
Mar 11 '26
Sale
52.80
9,798
517,334
235,558
Kulkarni Samarth
Chief Executive Officer
Feb 19 '26
Sale
52.58
6,967
366,325
226,106
$90.58
price down icon 2.44%
$119.52
price down icon 2.82%
$33.91
price down icon 1.77%
$58.43
price down icon 1.00%
$205.52
price up icon 0.02%
ONC ONC
$316.01
price down icon 1.88%
Capitalizzazione:     |  Volume (24 ore):